Q1 2025
Released Aug 6, 2024, after the close
10-Q filed Aug 6, 2024, 37 days after period end · 0001764013-24-000148
Q1 2025 · 10-Q
Revenue—
Net Income-$87.15M-$87.15M N/M vs Q1 2024N/M vs Q4 2024
EPS Diluted-$0.60-$0.60 N/M vs Q1 2024no prior Q4 2024 on file
Operating Cash Flow-$76,199,000N/M
Free Cash Flowderived-$76,381,000N/M
What the release said
The release
Same quarter
| Metric | Q1 2025 | Q1 2024 | Q1 2023 | Q1 2022 |
|---|---|---|---|---|
| Net Income | -$87.15M | -$73.94M | -$40.37M | -$30.47M |
| EPS Diluted | -$0.60 | -$0.57 | -$0.35 | -$0.31 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Immunovant, Inc. · CIK 1764013 · Engraved from SEC EDGAR